Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 4Terminated 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Ovarian Neoplasms 2Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 69Carboplatin 66Cisplatin 36pembrolizumab 34Gemcitabine 24liposomal doxorubicin 23Cyclophosphamide 23Topotecan 22Bevacizumab 20Taxes 14Docetaxel 13niraparib 12Nivolumab 12olaparib 10fludarabine 10Doxorubicin 9Surveys and Questionnaires 8Radiotherapy 8Oxaliplatin 8aldesleukin 7Filgrastim 7rucaparib 6oregovomab 6fludarabine phosphate 6durvalumab 6avelumab 6Interleukin-2 6Hyperthermic Intraperitoneal Chemotherapy 6Fluorodeoxyglucose F18 6Cytoreduction Surgical Procedures 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × farletuzumab × Gynecologic × Clear all
NCT00849667 2022-12-30

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

Morphotek

Phase 3 Terminated
1,100 enrolled 30 charts
Gynecologic

Ovarian Neoplasms

NCT01018563 2021-12-08

An Open Label Extension Study of the Efficacy of MORAb-003

Morphotek

Phase 2 Terminated
3 enrolled 12 charts
Gynecologic

Carcinoma, Ovarian Epithelial

NCT00738699 2017-03-30

FAR-122

Morphotek

Phase 2 Terminated
415 enrolled 11 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡